Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ABBV > SEC Filings for ABBV > Form 8-K on 15-May-2014All Recent SEC Filings

Show all filings for ABBVIE INC.

Form 8-K for ABBVIE INC.


Change in Directors or Principal Officers, Submission of Matters to a Vote of Securit

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 15, 2014, AbbVie Inc. ("AbbVie") announced that it has named Michael Severino, M.D. its new Executive Vice President, Research & Development and Chief Scientific Officer. Dr. Severino, 48, joins AbbVie from Amgen Inc., where he served as Senior Vice President, Global Development and Corporate Chief Medical Officer. In connection with Dr. Severino's appointment, he will receive compensation and benefits based on market data and programs available to similarly-situated AbbVie employees.

A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

AbbVie held its Annual Meeting of Stockholders on May 9, 2014. The following is a summary of the matters voted on at that meeting.

(1) The stockholders elected AbbVie's Class II Directors with terms expiring in 2017, as follows:

Name                        For         Withheld    Broker Non-Votes
Robert J. Alpern       1,116,453,438   19,270,145        223,235,590
Edward M. Liddy        1,118,006,383   17,717,200        223,235,590
Frederick H. Waddell   1,112,540,591   23,182,992        223,235,590

(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2014, as follows:

For Against Abstain
1,321,734,361 33,657,911 3,566,901

(3) The stockholders approved, on an advisory basis, the compensation of AbbVie's named executive officers listed in the proxy statement for the 2014 annual meeting, as follows:

For Against Abstain Broker Non-Votes 1,088,532,785 37,269,956 9,920,842 223,235,590

Item 9.01. Financial Statements and Exhibits.

Exhibit No. Exhibit
99.1 Press Release dated May 15, 2014.

  Add ABBV to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ABBV - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.